ADARx Pharmaceuticals, Inc. (ADRX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.89B USD. 52-week range 16.64 to 23.21 USD. Data as of 2026-10-09.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor ...